- EUR600K upfront payment upon signing the new amendment agreement - - EUR400K payment once launched in significant E.U. markets - - Deal also includes sales-based milestone payments, royalties and revenue pursuant to the supply agreement - - New amendme
Food-based commodity farming on up to 9 million hectares in KenyaBELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company and Farm 7 Group Inc., a Canada co
- Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 - - Company’s intellectual property portfolio now encompasses 2 granted U.S. patents, and over 50 pending pate
BURLINGTON, Ontario--(BUSINESS WIRE)--$ANRG #ANRG--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) today announced its financial results for the three- and six-month periods ended June 30, 2023 (“Q2 2023”), and the related management
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is p
TORONTO--(BUSINESS WIRE)--Greenbrook TMS Inc. (NASDAQ: GBNH) (“Greenbrook” or the “Company”), announced a correction to its press release originally dated August 9, 2023 announcing the release of its operational and financial results for the secon
– Enhances financial flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates – - The Company’s ending 2Q2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations i
- Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 - - U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 - Ended quarter with $34.3 million in cash and equivalentsTORONTO--(BUSINESS WIRE)--$AT
NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., today rep
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.